Treatment Patterns and Clinical Outcomes of Chronic Urticaria: Two-year Follow-up Results from the Scandinavian AWARE Study

Simon F. Thomsen; Ellen C. Pritzier; Chris D. Anderson; Siri Juvik; Nicolas V. Baust; Rikke Dodge; Anna Karin Dahlborn; Christian Vestergaard

doi:10.2340/actadv.v102.1620

Treatment Patterns and Clinical Outcomes of Chronic Urticaria: Two-year Follow-up Results from the Scandinavian AWARE Study

Simon F. Thomsen, Ellen C. Pritzier, Chris D. Anderson, Siri Juvik, Nicolas V. Baust, Rikke Dodge, Anna Karin Dahlborn, Christian Vestergaard^*

^*Corresponding author af dette arbejde

Inflammation, Metabolism and Oxidation

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

3 Citationer (Scopus)

12 Downloads (Pure)

Abstract

The AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) study investiga-ted outcomes in patients with chronic urticaria refractory to H1-antihistamine. The objective of the current study was to analyse the effects of treatment on pa-tients’ symptoms and quality of life for a period of up to 2 years. Over the 2 years, there was clear improvement in the high rates of disease burden from base-line, as evidenced by lower scores for disease severity scales, better quality of life, and a decreasing rate of medical resource utilization. However, this is the re-sult of treatment adherence to the guidelines in highly specialized Scandinavian urticaria centres, and has its basis in the relatively low treatment intensity and con-trol at enrolment. There is a need for greater adherence to the treatment guidelines and better management of antihistamine-refractory chronic urticaria.

Originalsprog	Engelsk
Artikelnummer	adv00689
Tidsskrift	Acta Dermato-Venereologica
Vol/bind	102
Sider (fra-til)	1-6
ISSN	0001-5555
DOI	https://doi.org/10.2340/actadv.v102.1620
Status	Udgivet - 2022

Bibliografisk note

Funding Information:
The authors acknowledge K. M. Ashwini Kumar (Novartis Healthcare Pvt Ltd, India), and Aafrin Khan (Novartis Healthcare Pvt Ltd, India) for editorial and writing support, in accordance with the Good Publication Practice (GPP3) guidelines (http://www. ismpp.org/gpp3). The study was funded by Novartis Pharma AG.

Funding Information:
The authors acknowledge K. M. Ashwini Kumar (Novartis Health-care Pvt Ltd, India), and Aafrin Khan (Novartis Healthcare Pvt Ltd, India) for editorial and writing support, in accordance with the Good Publication Practice (GPP3) guidelines (http://www. ismpp.org/gpp3). The study was funded by Novartis Pharma AG.

Publisher Copyright:
© 2022, Medical Journals/Acta D-V. All rights reserved.

Adgang til dokumentet

10.2340/actadv.v102.1620Licens: CC BY-NC

FulltextForlagets udgivne version, 389 KBLicens: CC BY-NC

Citationsformater

Treatment Patterns and Clinical Outcomes of Chronic Urticaria : Two-year Follow-up Results from the Scandinavian AWARE Study. / Thomsen, Simon F.; Pritzier, Ellen C.; Anderson, Chris D.; Juvik, Siri; Baust, Nicolas V.; Dodge, Rikke; Dahlborn, Anna Karin; Vestergaard, Christian.

I: Acta Dermato-Venereologica, Bind 102, adv00689, 2022, s. 1-6.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{77d0d86f1c934ccbb441a451c05704c3,

title = "Treatment Patterns and Clinical Outcomes of Chronic Urticaria: Two-year Follow-up Results from the Scandinavian AWARE Study",

abstract = "The AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) study investiga-ted outcomes in patients with chronic urticaria refractory to H1-antihistamine. The objective of the current study was to analyse the effects of treatment on pa-tients{\textquoteright} symptoms and quality of life for a period of up to 2 years. Over the 2 years, there was clear improvement in the high rates of disease burden from base-line, as evidenced by lower scores for disease severity scales, better quality of life, and a decreasing rate of medical resource utilization. However, this is the re-sult of treatment adherence to the guidelines in highly specialized Scandinavian urticaria centres, and has its basis in the relatively low treatment intensity and con-trol at enrolment. There is a need for greater adherence to the treatment guidelines and better management of antihistamine-refractory chronic urticaria.",

keywords = "AWARE, chronic urticaria, omalizumab, patient-reported outcomes, quality of life",

author = "Thomsen, {Simon F.} and Pritzier, {Ellen C.} and Anderson, {Chris D.} and Siri Juvik and Baust, {Nicolas V.} and Rikke Dodge and Dahlborn, {Anna Karin} and Christian Vestergaard",

year = "2022",

doi = "10.2340/actadv.v102.1620",

language = "English",

volume = "102",

pages = "1--6",

journal = "Acta Dermato-Venereologica",

issn = "0001-5555",

publisher = "Society for the Publication of Acta Dermato - Venereologica",

}

TY - JOUR

T1 - Treatment Patterns and Clinical Outcomes of Chronic Urticaria

T2 - Two-year Follow-up Results from the Scandinavian AWARE Study

AU - Thomsen, Simon F.

AU - Pritzier, Ellen C.

AU - Anderson, Chris D.

AU - Juvik, Siri

AU - Baust, Nicolas V.

AU - Dodge, Rikke

AU - Dahlborn, Anna Karin

AU - Vestergaard, Christian

PY - 2022

Y1 - 2022

N2 - The AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) study investiga-ted outcomes in patients with chronic urticaria refractory to H1-antihistamine. The objective of the current study was to analyse the effects of treatment on pa-tients’ symptoms and quality of life for a period of up to 2 years. Over the 2 years, there was clear improvement in the high rates of disease burden from base-line, as evidenced by lower scores for disease severity scales, better quality of life, and a decreasing rate of medical resource utilization. However, this is the re-sult of treatment adherence to the guidelines in highly specialized Scandinavian urticaria centres, and has its basis in the relatively low treatment intensity and con-trol at enrolment. There is a need for greater adherence to the treatment guidelines and better management of antihistamine-refractory chronic urticaria.

AB - The AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) study investiga-ted outcomes in patients with chronic urticaria refractory to H1-antihistamine. The objective of the current study was to analyse the effects of treatment on pa-tients’ symptoms and quality of life for a period of up to 2 years. Over the 2 years, there was clear improvement in the high rates of disease burden from base-line, as evidenced by lower scores for disease severity scales, better quality of life, and a decreasing rate of medical resource utilization. However, this is the re-sult of treatment adherence to the guidelines in highly specialized Scandinavian urticaria centres, and has its basis in the relatively low treatment intensity and con-trol at enrolment. There is a need for greater adherence to the treatment guidelines and better management of antihistamine-refractory chronic urticaria.

KW - AWARE

KW - chronic urticaria

KW - omalizumab

KW - patient-reported outcomes

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=85128248249&partnerID=8YFLogxK

U2 - 10.2340/actadv.v102.1620

DO - 10.2340/actadv.v102.1620

M3 - Journal article

C2 - 35166853

AN - SCOPUS:85128248249

VL - 102

SP - 1

EP - 6

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

SN - 0001-5555

M1 - adv00689

ER -